Wed, Oct 16, 2024
[Archive]
Volume 32, Issue 152 (May & June 2024)
J Adv Med Biomed Res 2024, 32(152): 168-173 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Shabani J, Hemmati M, Sedighi M. The Effect of Intermittent Oral Anticonvulsant Levetiracetam in Prevention of Recurrence of Febrile Seizure in Children: A Randomized Clinical Trial Study. J Adv Med Biomed Res 2024; 32 (152) :168-173
URL: http://journal.zums.ac.ir/article-1-7360-en.html
URL: http://journal.zums.ac.ir/article-1-7360-en.html
1- Kermanshah University of Medical Sciences, Kermanshah, Iran
2- Kermanshah University of Medical Sciences, Kermanshah, Iran ,sedighimostafa2000@gmail.com
2- Kermanshah University of Medical Sciences, Kermanshah, Iran ,
Abstract: (39 Views)
Background & Objective: Febrile seizure (FS) is the most common childhood seizure disorder that occurs in 3-4% of children .The aim of this study was to determine the effect of intermittent oral anticonvulsant Levetiracetam in prevention of the recurrence of febrile seizure (FS) in children.
Materials & Methods: This a randomized clinical trial study was conducted on 108 children with FS referred to the pediatric department of Mohammad Kermanshahi Hospital in Kermanshah in 2020. Then, eligible patients were divided into intervention (Levetiracetam; n= 72) and control (Acetaminophen; n= 36) groups using balanced block randomization. The intervention group received a dose of 30-60 mg/kg Levetiracetam during the febrile illness for prophylaxis for 9 months. In contrast, in the control group, only acetaminophen was prescribed just to reduce fever. Finally, the number of FS recurrences were studied in two groups. The data were analyzed using SPSS 26.
Results: The mean (±S.D) age were 2.37 (±1.01) vs. 2.30 (±0.95) years in the intervention and control groups; respectively. The number (%) of boys in the two groups under study was 39 (54.1) and 19 (52.7), respectively. The mean time to first seizure recurrence after the intervention was significantly longer in the intervention group (5.70 ± 0.82 months) than in the control group (2.32 ± 0.75 months) (P-Value<0.05). Also, the mean number of recurrences of FS in the intervention group (2.25 ± 0.80) was significantly lower than the control group (4.13 ± 0.79) (P-Value<0.05).
Conclusion: The administration of oral anticonvulsant Levetiracetam may be effective in the reduction of the recurrences of FS, however, detailed studies in this field is recommended.
Materials & Methods: This a randomized clinical trial study was conducted on 108 children with FS referred to the pediatric department of Mohammad Kermanshahi Hospital in Kermanshah in 2020. Then, eligible patients were divided into intervention (Levetiracetam; n= 72) and control (Acetaminophen; n= 36) groups using balanced block randomization. The intervention group received a dose of 30-60 mg/kg Levetiracetam during the febrile illness for prophylaxis for 9 months. In contrast, in the control group, only acetaminophen was prescribed just to reduce fever. Finally, the number of FS recurrences were studied in two groups. The data were analyzed using SPSS 26.
Results: The mean (±S.D) age were 2.37 (±1.01) vs. 2.30 (±0.95) years in the intervention and control groups; respectively. The number (%) of boys in the two groups under study was 39 (54.1) and 19 (52.7), respectively. The mean time to first seizure recurrence after the intervention was significantly longer in the intervention group (5.70 ± 0.82 months) than in the control group (2.32 ± 0.75 months) (P-Value<0.05). Also, the mean number of recurrences of FS in the intervention group (2.25 ± 0.80) was significantly lower than the control group (4.13 ± 0.79) (P-Value<0.05).
Conclusion: The administration of oral anticonvulsant Levetiracetam may be effective in the reduction of the recurrences of FS, however, detailed studies in this field is recommended.
Type of Study: Clinical Trials |
Subject:
Clinical medicine
Received: 2023/09/29 | Accepted: 2024/10/2 | Published: 2024/06/21
Received: 2023/09/29 | Accepted: 2024/10/2 | Published: 2024/06/21
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Copyright Policy
